An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway

Trial Profile

An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Temozolomide (Primary) ; Vismodegib (Primary)
  • Indications Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MEVITEM
  • Most Recent Events

    • 18 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 06 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2018.
    • 06 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top